134 related articles for article (PubMed ID: 27174789)
1. The role and indications of aggressive locoregional therapy in metastatic inflammatory breast cancer.
Yan Y; Tang L; Tong W; Zhou J
Sci Rep; 2016 May; 6():25874. PubMed ID: 27174789
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management.
Warren LE; Guo H; Regan MM; Nakhlis F; Yeh ED; Jacene HA; Hirshfield-Bartek J; Overmoyer BA; Bellon JR
Ann Surg Oncol; 2015 Aug; 22(8):2483-91. PubMed ID: 25791789
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.
Weiss A; Menen RS; Lin HY; Shen Y; Rosso KJ; Shaitelman S; Woodward W; Valero V; Ueno NT; Bedrosian I; Babiera G
Breast Cancer Res Treat; 2018 Jun; 169(3):615-623. PubMed ID: 29460033
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.
Saigal K; Hurley J; Takita C; Reis IM; Zhao W; Rodgers SE; Wright JL
Clin Breast Cancer; 2013 Oct; 13(5):335-43. PubMed ID: 23850216
[TBL] [Abstract][Full Text] [Related]
5. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
Fouad TM; Kogawa T; Liu DD; Shen Y; Masuda H; El-Zein R; Woodward WA; Chavez-MacGregor M; Alvarez RH; Arun B; Lucci A; Krishnamurthy S; Babiera G; Buchholz TA; Valero V; Ueno NT
Breast Cancer Res Treat; 2015 Jul; 152(2):407-16. PubMed ID: 26017070
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
van Uden DJ; Bretveld R; Siesling S; de Wilt JH; Blanken-Peeters CF
Breast Cancer Res Treat; 2017 Apr; 162(2):365-374. PubMed ID: 28138891
[TBL] [Abstract][Full Text] [Related]
7. Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer.
Loi M; Dunant A; Ghith S; Cascales-Garcia AM; Mazouni C; Pistilli B; Mathieu MC; Deutsch E; Arriagada R; Rivera S
Cancer Invest; 2019; 37(1):29-38. PubMed ID: 30656969
[TBL] [Abstract][Full Text] [Related]
8. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).
Dano D; Lardy-Cleaud A; Monneur A; Quenel-Tueux N; Levy C; Mouret-Reynier MA; Coudert B; Mailliez A; Ferrero JM; Guiu S; Campone M; de La Motte Rouge T; Petit T; Pistilli B; Dalenc F; Simon G; Lerebours F; Chabaud S; Bertucci F; Gonçalves A
ESMO Open; 2021 Aug; 6(4):100220. PubMed ID: 34303929
[TBL] [Abstract][Full Text] [Related]
9. Modern outcomes of inflammatory breast cancer.
Rehman S; Reddy CA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):619-24. PubMed ID: 22445003
[TBL] [Abstract][Full Text] [Related]
10. Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).
Slaoui M; Zoure AA; Mouh FZ; Bensouda Y; El Mzibri M; Bakri Y; Amrani M
BMC Cancer; 2018 Jul; 18(1):713. PubMed ID: 29976157
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery.
Brzezinska M; Williams LJ; Thomas J; Michael Dixon J
Breast Cancer Res Treat; 2016 Dec; 160(3):387-391. PubMed ID: 27757718
[TBL] [Abstract][Full Text] [Related]
12. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
13. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer.
Menta A; Fouad TM; Lucci A; Le-Petross H; Stauder MC; Woodward WA; Ueno NT; Lim B
Surg Clin North Am; 2018 Aug; 98(4):787-800. PubMed ID: 30005774
[TBL] [Abstract][Full Text] [Related]
16. MARCKS protein overexpression in inflammatory breast cancer.
Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory breast cancer: an overview.
van Uden DJ; van Laarhoven HW; Westenberg AH; de Wilt JH; Blanken-Peeters CF
Crit Rev Oncol Hematol; 2015 Feb; 93(2):116-26. PubMed ID: 25459672
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and outcome characteristics of inflammatory breast cancers in Brazzaville].
N'koua-M'bon JB; Bambara AT; Moukassa D; Gombé-Mbalawa C
Bull Cancer; 2013 Feb; 100(2):147-53. PubMed ID: 23392567
[TBL] [Abstract][Full Text] [Related]
19. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?
Nguyen DH; Truong PT; Alexander C; Walter CV; Hayashi E; Christie J; Lesperance M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):39-45. PubMed ID: 22330986
[TBL] [Abstract][Full Text] [Related]
20. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.
Alexander A; Karakas C; Chen X; Carey JP; Yi M; Bondy M; Thompson P; Cheung KL; Ellis IO; Gong Y; Krishnamurthy S; Alvarez RH; Ueno NT; Hunt KK; Keyomarsi K
Oncotarget; 2017 Feb; 8(9):14897-14911. PubMed ID: 28107181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
